Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, reported unaudited financial results for the third quarter ended Dec. 31, 2025. The company highlighted continued progress across its HLP003 Phase 3 program for major depressive disorder and HLP004 Phase 2 program for generalized anxiety disorder, along with a completed leadership transition and corporate rebranding.
Helus Pharma ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities. Management emphasized its strengthened balance sheet, expanding intellectual property portfolio and upcoming clinical data milestones in 2026. The company's cash position is expected to fund operations into 2027, providing a runway to reach key inflection points.
HLP003, a proprietary novel serotonergic agonist (NSA), is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs designed to activate serotonin pathways believed to promote neuroplasticity.
The company operates in Canada, the United States, the United Kingdom and Ireland. Helus Pharma is the commercial operating name of Cybin Inc., which was founded in 2019. The company aims to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
For more details, view the full press release at https://ibn.fm/VigPf and follow updates in the company's newsroom at https://ibn.fm/HELP.
